--- title: "10:30 ET\n\t\t\t\n\t\t\t\n\t\t\t\tUS Single-Cell Analysis Market worth US$2,695.3 million by 2029 with 14.3% CAGR | MarketsandMarkets™" description: "The US Single-Cell Analysis Market is projected to grow from US$1,378.6 million in 2024 to US$2,695.3 million by 2029, at a CAGR of 14.3%. Key growth factors include technological advancements, increa" type: "news" locale: "en" url: "https://longbridge.com/en/news/234835655.md" published_at: "2025-04-07T14:31:09.000Z" --- # 10:30 ET US Single-Cell Analysis Market worth US$2,695.3 million by 2029 with 14.3% CAGR | MarketsandMarkets™ > The US Single-Cell Analysis Market is projected to grow from US$1,378.6 million in 2024 to US$2,695.3 million by 2029, at a CAGR of 14.3%. Key growth factors include technological advancements, increased R&D funding, and a focus on personalized medicine. The market is segmented into consumables and instruments, with consumables expected to dominate. Flow cytometry is the leading technique. Challenges include high costs and ethical considerations. Major players include Thermo Fisher Scientific, Danaher, and Illumina. , /PRNewswire/ -- The **US Single-Cell Analysis Market** is projected to reach US$2,695.3 million by 2029 from an estimated US$1,378.6 million in 2024, at a CAGR of 14.3% from 2024 to 2029. Factors contributing to the growth of the US market include technological advancements, growing research and development fundings and investments, advancements in stem cell research, increasing number of cancer cases, and rising focus on personalized medicine. Also, growing adoption of single-cell sequencing and integration of microfluidic techniques with cell analysis are projected to support the growth of single-cell analysis market. However, high cost of single-cell analysis products is expected to hinder market growth. Technical challenges and ethical considerations associated with single-cell analysis might create hurdles to the growth of US single-cell analysis market. **Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171955254** **Browse in-depth TOC on "****US Single-Cell Analysis Market****"** **150 - Tables ****50 - Figures** **By Based on Product,** the US single-cell analysis market is segmented into consumables and instruments. The consumables segment is further divided into reagents, assay kits, beads, microplate, and other consumables. The instruments segment is further segmented into next-generation sequencing, microscopy, flow cytometry, polymerase chain reaction, mass spectrometry, and other techniques. The consumables segment dominated the market in 2023 and is expected to dominate the market in the forecast period. The largest share of the segment is attributed to the increasing demand for high-quality reagents to ensure reliable and reproducible results. Additionally, growing focus on development of advanced cellular therapies is anticipated to promote the segment growth. **By Based on end user,** the US single-cell analysis market is segmented into academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centers. The academic & research laboratories segment is estimated to register the highest growth rate during the forecast period. The rising focus on development of cell-based therapeutics due to growing incidences of cancer is expected to propel the segment growth. Additionally, increasing investments and fundings for life science research has increased the adoption of advanced technologies such as single-cell analysis, resulting to boost the segment growth in the market. **By Based on technique,** the US single-cell analysis market is segmented into flow cytometry, next-generation sequencing, polymerase chain reaction, microscopy, mass spectrometry, and other techniques. The flow cytometry segment dominated the market in 2023 and is expected to dominate the market in the forecast period. The large share of this segment can be attributed to the wide usage of flow cytometry in detecting and measuring the physical and chemical characteristics of a population of cells or particles. The growing adoption of flow cytometry for stem cell research and regenerative medicines is promoting the growth of the segment. Growth in this segment is primarily driven by the wide usage of flow cytometry in single-cell analysis applications due to its ability to perform multiple measurements on single cells within a heterogeneous mixture. **Request Sample Pages :** **https://www.marketsandmarkets.com/requestsampleNew.asp?id=171955254** Key players in the single-cell analysis market include Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), BD (US), Agilent Technologies, Inc. (US), 10x Genomics (US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Standard BioTools (US), Corning Incorporated (US), Cytek Biosciences (US), Revvity (US), Bio-Techne (US), PacBio (US), Bruker (US), Promega Corporation (US), Fluent BioSciences (US), RareCyte, Inc. (US), Cell Microsystems (US), and NanoCellect Biomedical (US). For more information, **Inquire Now!** **Related Reports:** **Flow Cytometry Market** **Next-Generation Sequencing Market** **Digital PCR (dPCR) and Real-time PCR (qPCR) Market** **Stem Cell Therapy Market** **Cell Analysis Market** **About MarketsandMarkets™:** MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, **80% of Fortune 2000 companies rely on MarketsandMarkets**, and **90 of the top 100 companies in each sector trust us to accelerate their revenue growth**. With a **global clientele of over 13,000 organizations**, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our **Market Intelligence Cloud, KnowledgeStore™**, which integrates research and provides ecosystem-wide visibility into revenue shifts. In addition, **MarketsandMarkets SalesIQ** enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitte , LinkedIn and Facebook . **Contact: Mr. Rohan Salgarkar **MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: \[email protected\] Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets\_Logo.jpg SOURCE MarketsandMarkets ### Related Stocks - [TMO.US - Thermo Fisher Scentific](https://longbridge.com/en/quote/TMO.US.md) - [DHR.US - Danaher](https://longbridge.com/en/quote/DHR.US.md) - [ILMN.US - Illumina](https://longbridge.com/en/quote/ILMN.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 布鲁克代尔老年关怀公司｜8-K：2025 财年 Q4 营收 7.54 亿美元 | | [Link](https://longbridge.com/en/news/276272851.md) | | 伟世通｜8-K：2025 财年 Q4 营收 9.48 亿美元超过预期 | | [Link](https://longbridge.com/en/news/276330340.md) | | 休曼纳｜10-K：2025 财年营收 1287 亿美元不及预期 | | [Link](https://longbridge.com/en/news/276370855.md) | | 布鲁克代尔老年关怀公司｜10-K：2025 财年营收 30.54 亿美元 | | [Link](https://longbridge.com/en/news/276380056.md) | | Illumina｜8-K：2025 财年 Q4 营收 11.59 亿美元超过预期 | | [Link](https://longbridge.com/en/news/275031316.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.